Related references
Note: Only part of the references are listed.Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
Paul Guedeney et al.
EUROPEAN HEART JOURNAL (2022)
Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis
Hangying Ying et al.
CARDIOVASCULAR DRUGS AND THERAPY (2021)
PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database
Gabriella di Mauro et al.
DRUG SAFETY (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Lipid Lowering and Alzheimer Disease Risk: A Mendelian Randomization Study
Dylan M. Williams et al.
ANNALS OF NEUROLOGY (2020)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
Emma M. O'Connell et al.
FRONTIERS IN NEUROSCIENCE (2020)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study
Cynthia Picard et al.
PLOS ONE (2019)
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Peter W. F. Wilson et al.
CIRCULATION (2019)
PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
Massimo R. Mannarino et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease
Martine Paquette et al.
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY (2018)
PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)
Matthew T. Mefford et al.
CIRCULATION (2018)
Intensive LDL-cholesterol lowering therapy and neurocognitive function
Maciej Banach et al.
PHARMACOLOGY & THERAPEUTICS (2017)
PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N-of-1 Trials
Kristopher J. Swiger et al.
DRUG SAFETY (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
EP van Puijenbroek et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2002)
A data mining approach for signal detection and analysis
A Bate et al.
DRUG SAFETY (2002)
Share Paper
